Clinical trials and research studies

This trial looks at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors (NSCLC, HNSCC).

The purpose of the study is to test BGB-11417 (alone, with dexamethasone, and with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma who test positive for t(11;14). .

The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).

The purpose of this study is to assess the effect of BMS-986446 vs placebo on delay of cognitive memory and functional decline in participants (age 50-80) with early Alzheimer's Disease.

The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine, to determine whether it delays or slows the progression of the symptoms of early Alzheimer’s disease.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.

PURPOSE: This is a biological sample collection study aimed at developing an early diagnostic tool for endometrial and ovarian cancer. The investigators are studying the relationship between estrogen driven gynecological cancers, inflammation and the microbiome. Patients who have been diagnosed with endometrial cancer or undergo presurgical evaluation for suspicion of ovarian cancer who are scheduled for a hysterectomy, bilateral oophorectomy and/or salpingectomy are eligible. Control patients undergoing gynecological surgery for benign indications are also being recruited.

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-).